Shann Kerner

Member

Direct 617-227-4349
Fax 781-622-5933
Boston, MA

Waltham, MA

Dr. Shann Kerner has substantial experience advising emerging, mid-sized and public companies in the biotechnology, pharmaceutical and medical device fields, counseling them on the creation, leveraging and protection of IP, with a view towards strengthening the business strategy of her clients.

A versatile and seasoned member of the Intellectual Property department, Shann concentrates her practice on IP counseling, particularly on patent portfolio procurement and management and IP due diligence in connection with venture capital, mergers and acquisitions, IPOs, and internal audits. Shann also focuses on analyses regarding patentability, freedom-to-operate, inventorship, derivation, validity and competitive subject matter landscape.

Shann's areas of technical concentration encompass molecular biology, microbiology, biochemistry, immunology, virology, cell biology, neurology and plant biology. Her practice includes clients in the fields of cancer and inflammatory disorders, early and late stage disease diagnostics and therapeutics, drug delivery, pharmaceuticals, nanotech, ophthalmology, antibodies, stem cells and medical devices, among others.

Prior to pursuing her legal career, Shann held a joint appointment as a faculty member at Harvard Medical School, Department of Neuropathology and at Boston Children's Hospital, Department of Developmental Neurobiology.

  • Procurement and management of company and university patent portfolios
  • Growth and positioning of a university patent portfolio for licensing
  • Offensive and defensive patent protection of products for an emerging company
  • Pre-litigation counseling for a medical device company
  • Pre-litigation counseling for a University
  • Representation of a branded pharmaceutical company in ANDA and antitrust litigations
  • Representation of branded biotechnology companies in patent infringement litigations
  • Representation of a medical equipment company in a patent litigation
  • Strategic positioning of a biotech company for cross-licensing or acquisition inventorship analysis for pharmaceutical company
  • Creation of university spinoff companies
  • Creation of affiliate foreign companies based on US IP

Panelist, The Evolving Aftermath of Licensing Agreements: Keeping Track of What is Important to Ensure Their Success

Post Licensing Issues: What Happens After the License is Signed, AUTM Eastern Regional Meeting

Creating and Monetizing Intellectual Property

The Evolving Aftermath of Licensing Agreements: Keeping Track of What is Important to Ensure Their Success

Post Licensing Issues: What Happens After the License is Signed, AUTM Eastern Regional Meeting

U.S./Russia Cross-border Opportunities in the Life Sciences Industry

Creating and Monetizing Intellectual Property

Russia-Focused Venture Capital Supports In-Bound Technology Transfer and Company Building: An Analysis of Investment Trends and Outcomes, Journal of Commercial Biotechnology

Patentability of Gene Sequences OK for Now, Medical Research & Policy Report, Bureau of National Affairs

Meeting the Bears: Gauging the Business Climate for Life Sciences of Russia, Life Science Law & Industry

Education
  • Suffolk University Law School, J.D.
  • Harvard Medical School and Children's Hospital, Post-Doctoral Fellowship
  • University of Connecticut Medical School, Ph.D.
  • Boston University, A.B.
Admissions
  • U.S. Patent & Trademark Office
  • Massachusetts Bar
  • U.S. District Court for the District of Massachusetts
  • Court of Appeals for the Federal Circuit
Practice Areas
Industries
Languages Spoken
  • French